Literature DB >> 27894986

Application of molecular genotyping to determine prevalence of HPV strains in Pap smears of Kazakhstan women.

Luiza Niyazmetova1, Gulzhanat Aimagambetova1, Nazigul Stambekova2, Zaurech Abugalieva3, Korlukain Seksembayeva3, Syed Ali1, Azliyati Azizan4.   

Abstract

OBJECTIVES: Human papillomavirus is the main causative agent for cervical cancer. However, few data are available about HPV prevalence in Kazakhstan. The aims of this study were to genotype HPV DNA in Pap smear samples of women to determine prevalence of carcinogenic HPV types in Astana, Kazakhstan and to analyze the association between HPV positivity and the cytology results of patient samples.
METHODS: Pap smear materials were obtained from 140 patients aged 18-59, who visited the outpatient gynecological clinic. Microscopic examination was done to detect dysplasia, and HPV genotyping was done using real-time multiplex PCR.
RESULTS: HPV testing showed that among 61 HPV positive patients, the most prevalent types were 16 and 18. Microscopic examination showed that 79% of the samples had normal cytology, while 13% had CIN grade I, 5% had CIN grade II, and 3% had CIN grade III. The analysis revealed that 12% of the samples had CIN cytology and presence of HPV. Approximately 31% had HPV without cervical dysplasia, while 8% of samples were CIN positive without HPV infection. A statistically significant relationship between HPV 16 and HPV 33 positive samples and CIN grade II and III was found.
CONCLUSIONS: Overall, this study will help to strengthen and guide health policy implementation of primary and secondary cervical cancer prevention strategies in Kazakhstan.
Copyright © 2016 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  CIN; HPV; Kazakhstan; cervical cancer; prevalence

Mesh:

Substances:

Year:  2016        PMID: 27894986     DOI: 10.1016/j.ijid.2016.11.410

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  7 in total

1.  What Factors Are Associated with Attitudes towards HPV Vaccination among Kazakhstani Women? Exploratory Analysis of Cross-Sectional Survey Data.

Authors:  Gulzhanat Aimagambetova; Aisha Babi; Torgyn Issa; Alpamys Issanov
Journal:  Vaccines (Basel)       Date:  2022-05-23

Review 2.  Epidemiology of HPV Infection and HPV-Related Cancers in Kazakhstan: a Review

Authors:  Gulzhanat Aimagambetova; Azliyati Azizan
Journal:  Asian Pac J Cancer Prev       Date:  2018-05-26

3.  HPV genotype prevalence and distribution during 2009-2018 in Xinjiang, China: baseline surveys prior to mass HPV vaccination.

Authors:  Jing Wang; Dandan Tang; Kai Wang; Jialu Wang; Zhaoxia Zhang; Yanxia Chen; Xueliang Zhang; Cailing Ma
Journal:  BMC Womens Health       Date:  2019-07-08       Impact factor: 2.809

Review 4.  Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination-Review of Current Perspectives.

Authors:  Chee Kai Chan; Gulzhanat Aimagambetova; Talshyn Ukybassova; Kuralay Kongrtay; Azliyati Azizan
Journal:  J Oncol       Date:  2019-10-10       Impact factor: 4.375

5.  Knowledge and awareness of human papillomavirus infection and human papillomavirus vaccine among Kazakhstani women attending gynecological clinics.

Authors:  Torgyn Issa; Aisha Babi; Alpamys Issanov; Ainur Akilzhanova; Kadisha Nurgaliyeva; Zauresh Abugalieva; Azliyati Azizan; Saleem A Khan; Chee Kai Chan; Raushan Alibekova; Gulzhanat Aimagambetova
Journal:  PLoS One       Date:  2021-12-13       Impact factor: 3.240

6.  A unique Levey-Jennings control chart used for internal quality control in human papillomavirus detection.

Authors:  Peiyi Peng; Xuehong Peng; Xiaoyang Jiao; Nuan Chen
Journal:  Virol J       Date:  2022-07-28       Impact factor: 5.913

7.  HPV infection and P16 expression in oral and oropharyngeal cancer in Kazakhstan.

Authors:  Dauren Adilbay; Galim Adilbayev; Gulzhan Kidirbayeva; Viktoria Shipilova; Zhanat Sadyk; Gulsum Koyanbekova; Ekaterina Sokolenko; Jan Klozar
Journal:  Infect Agent Cancer       Date:  2018-01-12       Impact factor: 2.965

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.